Available Until 10/18/2022

Geriatric Pharmacy Specialty Recertification Literature Study: Module 1A-C (Cert # L229124)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/16/2022
Content Release Date: 04/13/2022
Expiration Dates: 10/18/2022
Activity Type: Application-based
CE Credits: 15 hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A Antimicrobial Stewardship and Medication Issues in the Elderly: This module focuses on the use of antimicrobials and appropriate treatment of infections in the older adult population, as well as medication issues specific to the older adult population, such as deprescribing, prescribing cascades, and statin use. 

Module 1B Cardiology-Atrial Fibrillation and Anticoagulation: This module focuses on the appropriate treatment of atrial fibrillation and the use of anticoagulation agents in the older adult population. 

Module 1C Cardiology-HTN and Heart Failure: This module focuses on the treatment and monitoring of heart failure and hypertension in the older adult population. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCGP recertification approved by the BPS. 

The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 15 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete the assessments.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Geriatric Pharmacy Literature Study Module 1A: Antimicrobial Stewardship and Medication Issues in the Elderly

0204-9999-22-948-H01-P

5.0

80%

Geriatric Pharmacy Literature Study Module 1B: Cardiology-Atrial Fibrillation and Anticoagulation

0204-9999-22-949-H01-P

4.0

70%

Geriatric Pharmacy Literature Study Module 1C: Cardiology-HTN and Heart Failure

0204-9999-22-950-H01-P

6.0

73%

Module 1A: Antimicrobial Stewardship and Medication Issues in the Elderly      
ACPE Number:0204-9999-22-948-H01-P

This module focuses on the use of antimicrobials and appropriate treatment of infections in the older adult population, as well as medication issues specific to the older adult population, such as deprescribing, prescribing cascades, and statin use.

Nace DA, Hanlon JT, Crnich CJ et al. A multifaceted antimicrobial stewardship program for the treatment of uncomplicated cystitis in nursing home residents. JAMA Intern Med. 2020; 180(7):944-951.

Learning Objectives:

  • Describe the multifaceted antimicrobial stewardship program for the treatment of uncomplicated cystitis in nursing home residents study by Nace and colleagues.
  • Recommend antimicrobial stewardship interventions for nursing home residents with uncomplicated cystitis.

Rowe TA, Jump RLP, Marit Andersen B et al. Reliability of nonlocalizing signs and symptoms as indicators of the presence of infection in nursing-home residents. Infect Cont Hosp Epidemiol. 2020; 1-10. doi: 10.1017/ice.2020.1282. Epub ahead of print. PMID: 33292915.

Learning Objectives:

  • Describe the Society for Healthcare Epidemiology of America (SHEA) guidance statement on the reliability of nonlocalizing signs and symptoms as indicators of the presence of infection in nursing home residents.
  • Apply recommendations from the Society for Healthcare Epidemiology of America (SHEA) guidance statement to scenarios in which nursing home residents are exhibiting nonlocalizing signs and symptoms of infection.

Achterhof AB, Rozsnyai Z, Reeve E et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing. PLoS One. 2020; 15(10):e0240463. Published 2020 Oct 26. doi:10.1371/journal.pone.0240463

Learning Objectives:

  • Describe the study by Achterhof and colleagues about attitudes of older adults towards deprescribing.
  • Recommend deprescribing methods to increase older adult patients’ awareness of potentially inappropriate medications (PIMs).

Mack DS, Baek J, Tjia J et al. Statin discontinuation and life-limiting illness in non-skilled stay nursing homes at admission. J Am Geriatr Soc. 2020; 68(12):2787-2796.

Learning Objectives:

  • Describe the study by Mack and colleagues regarding statin discontinuation and life-limiting illness at nursing home admission.
  • Evaluate characteristics associated with statin discontinuation in nursing home patients with life-limiting illness.

Savage RD, Visentin JD, Bronskill SE et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020; 180(5):643-651.

Learning Objectives:

  • Describe the evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension study by Savage and colleagues.
  • Develop recommendations to minimize the risk of prescribing cascades in older adults with hypertension.

Sluggett JK, Hopkins RE, Chen EYH et al. Impact of medication regimen simplification on medication administration times and health outcomes in residential aged care: 12 month follow up of the SIMPLER randomized controlled trial. J Clin Med. 2020; 9(4):1053. Published 2020 Apr 8. doi:10.3390/jcm9041053.

Learning Objectives:

  • Describe the 12-month follow-up study to the SIMPLER trial by Sluggett and colleagues.
  • Develop recommendations to simplify medication regimens for older adults in long-term-care facilities.

Module 1B: Cardiology-Atrial Fibrillation and Anticoagulation
ACPE Number: 0204-9999-22-949-H01-P 

This module focuses on the appropriate treatment of atrial fibrillation and the use of anticoagulation agents in the older adult population.

Jones WS, Mulder H, Wruck LM et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021; 384:1981-1990.

Learning Objectives:

  • Describe the study by Jones and colleagues comparing the effectiveness and safety of two aspirin dosages in older adults with established cardiovascular disease.
  • Develop recommendations for the use of aspirin in older adults with established atherosclerotic cardiovascular disease (ASCVD).

Okumura K, Akao M, Yoshida T et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020; 383:1735-1745.

Learning Objectives:

  • Describe the study of the low-dose edoxaban in very elderly patients with atrial fibrillation study (ELDERCARE-AF) by Okumura and colleagues.
  • Develop recommendations for the use of oral anticoagulants in very elderly adult patients with atrial fibrillation.

Lopes RD, Heizer G, Aronson R et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019; 380(16):1509-1524.

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the AUGUSTUS study of antithrombotic drug therapy in older adults with atrial fibrillation and recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) who plan to receive a P2Y12 inhibitor.
  • Develop recommendations for the use of antithrombotic drug therapy in older adults with atrial fibrillation and recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI).

Kirchhof P, Camm AJ, Goette A et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383(14):1305-1316.

Learning Objectives:

  • Describe the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) by Kirchhof and colleagues of early rhythm-control therapy for older adult patients with atrial fibrillation.
  • Develop recommendations for the use of rhythm-control therapy in older adult patients with atrial fibrillation.

Module 1C: Cardiology-HTN and Heart Failure
ACPE Number: 0204-9999-22-950-H01-P

This module focuses on the treatment and monitoring of heart failure and hypertension in the older adult population.

Maddox TM, Januzzi JL, Allen LA et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77:772-810.

Learning Objectives:

  • Describe the expert consensus decision pathway from the American College of Cardiology for optimizing heart failure treatment in patients with reduced ejection fraction.
  • Develop recommendations for the management of patients with heart failure with reduced ejection fraction.

Anderson TS, Jing B, Auerbach A et al. Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge. JAMA Intern Med. 2019; 179(11):1528-1536.

Learning Objectives:

  • Describe the study of intensifying older adults’ antihypertensive medication regimens at hospital discharge.
  • Develop recommendations for antihypertensive drug therapy in older adults upon hospital discharge.

Pajewski NM, Berlowitz DR, Bress AP et al. Intensive vs standard blood pressure control in adults 80 years or older: a secondary analysis of the systolic blood pressure intervention trial. J Am Geriatr Soc. 2020; 68(3):496-504.

Learning Objectives:

  • Describe the study comparing intensive versus standard blood pressure control in older adults.
  • Develop recommendations for managing systolic blood pressure in older adults with hypertension.

Sheppard JP, Burt J, Lown M et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older. JAMA. 2020; 323(20):2039-2051.

Learning Objectives:

  • Describe the OPTIMISE study of the effect of reducing antihypertensive medications on blood pressure control in older adult patients.
  • Recommend whether to reduce antihypertensive medications in older adults.

Sheppard JP, Lown M, Burt J et al. Generalizability of blood pressure lowering trials to older patients: cross-sectional analysis. J Am Geriatr Soc. 2020; 68(11):2508-2515.

Learning Objectives:

  • Describe the study that analyzed whether pivotal hypertension management studies are generalizable to older adults.
  • Evaluate the applicability of hypertension trial findings to older adult patients.

McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21):1995-2008.

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study of dapagliflozin in older adult patients with heart failure and reduced ejection fraction with or without type 2 diabetes mellitus.
  • Develop recommendations for the use of dapagliflozin in older adults with heart failure and reduced ejection fraction with or without type 2 diabetes mellitus.

Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15):1413-1424.

Learning Objectives:

  • Describe the EMPEROR-Reduced study of empagliflozin in older adult patients with heart failure with a reduced ejection fraction with or without type 2 diabetes mellitus.
  • Develop recommendations for the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in older adult patients with heart failure with a reduced ejection fraction with or without type 2 diabetes mellitus.

Full Faculty Bios

Collin M. Clark
Clinical Assistant Professor
Department of Pharmacy Practice
University of Buffalo School of Pharmacy and Pharmaceutical Sciences
Buffalo, New York 

Jeannie Lee
Assistant Dean - Student Services
Associate Professor – Geriatrics
General Internal Medicine and Palliative Medicine
The University of Arizona College of Pharmacy
Tucson, Arizona 

Kari A. Mergenhagen
PGY2 ID Residency Director
VA Western New York Healthcare System
Buffalo, New York 

Ashley Schenk
Cardiology Clinical Pharmacist
University of Kentucky HealthCare
Lexington, Kentucky 

Laura Tsu
Associate Professor of Pharmacy Practice
Chapman University
School of Pharmacy
Irvine, California

Content Matter Experts

Amie Taggart Blaszczyk, Pharm.D., BCGP, BCPS, FASCP
Associate Professor of Geriatric Pharmacy Practice
Division Head of Geriatrics
Texas Tech University Health Sciences Center
School of Pharmacy
Dallas, Texas 

Dana G. Carroll, Pharm.D., BCGP, BCPS, CDE
Clinical Professor
Auburn University Harrison School of Pharmacy
University of Alabama Family Medicine
Auburn, Alabama 

Maria Shin, Pharm.D., BCGP, BCPS
Clinical Pharmacy Specialist in Internal Medicine
Robley Rex Louisville Veterans Affairs Medical Center
Louisville, Kentucky 

Holly L.Byrnes, Pharm.D., BCPS
Anna Jackson

Julia Bradshaw, Pharm.D., BCGP, BCPS
Bethany Coleman, Pharm.D., BCGP
Mark Crist, Pharm.D., BCPS, BCGP
Kira  Durr , Pharm.D., BCGP
Noor Fattouh, Pharm.D., BCGP
Nola Finke, Pharm.D., BCGP
Victoria Freberg, Pharm.D., BCGP
May Fung, Pharm.D., BCGP
Jennifer Gordon, B.Pharm (Hons), BCGP, MPS
Kimberly Graham, Pharm.D., BCGP, BCPS
Kathy Grams, Pharm.D., BCGP
Kyle Harris, Pharm.D., RPh, BCGP, LDE, CFTS
Lynn Hollaway, Pharm.D., MPH, BCGP, APh
Renee Hornsby, Pharm.D., BCGP
Samuel Hubler, Pharm.D., MSHCA, BCGP
Ernest Imatdinov, Pharm.D., BCGP
Klara Janis, Pharm.D., BCACP, BCGP, CDCES
Megan Kaiser, Pharm.D., BCPS, BCGP
Amy Kelleh, Pharm.D., BCGP
Susan King, Pharm.D., BCGP
Donzetta Landry, RPH, BCGP
Brian Leonard, Pharm.D., BCACP, BCGP
Giselle Leung, Pharm.D., BCGP
Jacob Mock, Pharm.D., BCGP
Jenna Nikesch, Pharm.D., BCGP
Francess Onwuchekwa, Pharm.D., MBA, BCGP
Robin Parker, Pharm.D., BCGP
Palak Patel, Pharm.D., BCGP, BCPS
Jennifer Peng, Pharm.D., BCGP
Zahava Picado, Pharm.D., BCGP
Polina Plotkin, Pharm.D., BCACP, BCGP
Muhammad Qudoos, Pharm.D., BCGP
Carly Ranson, Pharm.D., BCGP
Melissa Reilly, Pharm.D., BCGP
Nahirony  Sanchez, Pharm.D., BCGP, BCPS
Eric Set, Pharm.D., BCGP, APh
Zubila Shafiq, Pharm.D., BCGP
Yang-Yi Shemesh, Pharm.D., BCGP
Garcia Simon-Clarke, M.S., Pharm.D., BCNP, BCGP, BCPS
Abigail Steele, Pharm.D., BCPS, BCGP
Birgit Swartwout, R.Ph., BCGP
Anh Tran, Pharm.D., BCGP
Julia  Wasser, Pharm.D., BCGP
Alana Whittaker, Pharm.D., BCPS, BCGP
Christine Wu, Pharm.D., BCPS, BCGP
Kirstie Yi, Pharm.D., BCGP, BCPS

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP and ACCP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP and ACCP.